Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults
Phase of Trial: Phase II/III
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Ethyl eicosapentaenoic acid (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Pharmacodynamics; Proof of concept
- Acronyms BRAVE-EPA
- 10 Jun 2017 Biomarkers information updated
- 25 Jan 2017 Status changed from not yet recruiting to recruiting.
- 17 Oct 2016 Planned End Date changed from 1 Apr 2021 to 1 Nov 2021.